SCHEMBL12781148

SCHEMBL12781148

CNCCOc1ccc2nc(-n3nc(Nc4ccc(S(N)(=O)=O)cc4)nc3N)sc2c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BACE1 P56817 4/20 0.51
▸ AXL P30530 2/20 0.47
▸ JAK2 O60674 3/20 0.43
▸ CCNB2 O95067 3/20 0.42
▸ CDK1 P06493 3/20 0.42
▸ CCNB1 P14635 3/20 0.42
▸ CCNB3 Q8WWL7 3/20 0.42
▸ CA1 P00915 3/20 0.40
▸ CA2 P00918 3/20 0.40
▸ CA12 O43570 2/20 0.40
▸ CA9 Q16790 2/20 0.40
▸ CA4 P22748 2/20 0.40
▸ CCNA2 P20248 4/20 0.40
▸ CDK2 P24941 4/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ CA3 P07451 1/20 0.39
▸ PKM P14618 1/20 0.39
▸ CA6 P23280 1/20 0.39
▸ CA5A P35218 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12781185 0.97 BACE1 (0.51) BACE1AXLJAK2CCNB2CDK1
SCHEMBL12781140 0.91 BACE1 (0.53) BACE1AXLJAK2CCNB2CDK1
SCHEMBL12781085 0.90 BACE1 (0.53) BACE1AXLJAK2CCNB2CDK1
SCHEMBL12781162 0.89 IKBKB (0.51) BACE1AXLJAK2CCNB2CDK1
SCHEMBL12781025 0.87 CA2 (0.51) BACE1AXLJAK2CCNB2CDK1
SCHEMBL12781101 0.86 BACE1 (0.62) BACE1AXLINSR
SCHEMBL12781103 0.86 JAK2 (0.51) BACE1AXLJAK2CCNB2CDK1
SCHEMBL12781098 0.84 BACE1 (0.61) BACE1AXLCA1CA2CA9
SCHEMBL2088260 0.83 BACE1 (0.50) BACE1AXLJAK2CCNB2CDK1
SCHEMBL12781118 0.80 CCNB2 (0.49) AXLJAK2CCNB2CDK1CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 — — US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 — — US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 — — US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 — — US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 — — US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 BACE1 3044/4885AXL 762/4885JAK2 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback